AstraZeneca PLC
1 February 2001
ASTRAZENECA & IBM SIGN GLOBAL STRATEGIC OUTSOURCING AGREEMENT WORTH $1.7
billion
One of the world's largest pharmaceuticals companies - AstraZeneca - and IBM,
the world's largest information technology company, today announced that they
had signed a global strategic outsourcing agreement worth $1.7 billion over
seven years. The agreement, covering the provision of IT infrastructure
services to 45 countries, is the largest of its kind in the pharmaceuticals
industry.
Under this agreement, IBM will provide a range of IT services to AstraZeneca
throughout its global organisation. These cover PC Management, network and
communications services, including E-Mail, and computer operations support.
AstraZeneca will retain control of its IT technical strategy and the
development and support of its application systems.
Paul Burfitt, Chief Information Officer of AstraZeneca, said, 'Our partnership
with IBM will enable AstraZeneca to concentrate the effort of its Information
Services (IS) capabilities on such strategic opportunities as e-business and
informatics in R&D, and to further encourage added value from IS activities.
This partnership will give AstraZeneca access to greater expertise and
resource world-wide and will enhance competitive edge. It will also provide
additional career and personal development opportunities for IT professionals
joining IBM.'
Frank Kern, General Manager, Professional Services, IBM Global Services,
said, 'This alliance joins two world class players. Our combined strengths,
global reach and culture will enable AstraZenenca to optimise its global IT
infrastructure and create business value. IBM will contribute its proven
skills and expertise in leveraging technology. This will ensure a robust IT
infrastructure to support AstraZeneca's fast moving business, allowing the
organisation to focus on strategic IS opportunities.'
Up to 1200 AstraZeneca staff currently involved in the provision of IT
services, principally from the US, UK and Sweden, will transfer to IBM. No
redundancies are anticipated.
1 February 2001
Further enquiries to:
Michael Olsson Tel +44 (0)20 7304 5087
Ed Seage Tel +44 (0)20 7304 5101
Jorgen Winroth Tel +1 609 896 4148
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.